Chronic Obstructive Pulmonary Disease Clinical Trial
— Tie-COPDOfficial title:
Early Intervention With Tiotropium (Spiriva) in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel, Multicentre Trial
Chronic obstructive pulmonary disease (COPD) is one of the commonest respiratory diseases.
During the early stage of COPD, patients only have mild respiratory symptoms or signs which
may lead to under-diagnosis of the disease. Patients may show poor response to treatment at
later stages of the disease, associated with higher mortality and incidence of
re-hospitalization and disability causing burden for both the families and the society.
So far, there is no large-scale clinical trial on long-term intervention with tiotropium
bromide (Spiriva) in patients with early stages of COPD (i.e. GOLD Stage I-II COPD or
asymptomatic COPD). It would be of great significance for COPD prevention and treatment if
the investigators could prove that tiotropium decreases the lung function decline and
reverses disease progression in patients with early-stage COPD.
The investigators objective is to evaluate the efficacy of long-term intervention with
tiotropium in early stage (FEV1 ≥50% predicted) COPD (difference of trough FEV1, number of
exacerbations, time to first exacerbation, quality of life, etc) and relevant
pharmacoeconomic endpoints.
Status | Completed |
Enrollment | 841 |
Est. completion date | August 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 40 Years to 85 Years |
Eligibility |
Inclusion Criteria: - Age: 40-85 yrs, both male and female, with or without smoking history, receiving treatment in community hospitals or outpatient department in general hospitals - GOLD Stage I-II COPD: FEV1/FVC<70% and FEV1=50% predicted, measured 20min after 400µg salbutamol inhalation - With stable COPD: no COPD exacerbation during the latest 4 weeks prior to the recruitment - With capability of communicating via oral conversation or written documents and signing informed consent - With agreement to receive and are capable of participating in study related auxiliary examinations - Capability of proper use of HandiHaler Exclusion Criteria: - Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the patients' ability to participate in the study - Patients with clinically significant abnormal baseline haematology, blood biochemistry or urinary analysis, if the abnormality defines a significant disease as defined in exclusion criteria No. 1 - Patients with clinical diagnosis of lung cancer, bronchiectasis, pneumoconioses, or other single restricted ventilation - Severe cardiovascular, neural, hepatic, renal and hematologic diseases or malignancies that may interfere with the operation of the study - Patients with prostatic hyperplasia or bladder neck obstruction with significant symptoms, or narrow angle glaucoma - Patients with known moderate to severe impaired renal function in the opinion of the investigator or creatinine clearance =50 ml/min - Patients with history of asthma, allergic rhinitis, or who have a blood eosinophil count =600/mm^3 - Patients with active pulmonary tuberculosis - Patients with life-threatening pulmonary embolism, a1-antitrypsin deficiency, or cystic fibrosis - History of pneumonectomy - COPD exacerbation in 4 weeks prior to the first visit (V0), or hospitalization and/or antibiotic application and/or oral or intravenous glucocorticosteroids application is required during screening stage. - Treated with one of the trial drugs during the 30 days or 6 half-lives prior to the first visit (V0), with the selection of the longer period - Long-term oxygen therapy, frequent use of glucocorticosteroids orally or intravenously at unstable doses(i.e. less than six weeks on stable doses) or at doses in excess of the equivalent of 10 mg of prednisone/day, or long-term use of antibiotics - Pregnancy, lactation or potential of pregnancy - Planned hospitalization or blood donation during the trial - Known hypersensitivity or intolerance to trial drugs - History of chronic alcohol or drug abuse, or any other conditions that may impact compliance - Involvement in other clinical studies at the same time |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Beijing Chao-Yang Hospital | Beijing | Beijing |
China | The Second People's Hospital of Hunan Province | Changsha | Hunan |
China | Chenzhou No.1 people's Hopital | Chenzhou | Hunan |
China | Xinqiao Hospital | Chongqing | Chongqing |
China | The First People's Hospital of Foshan | Foshan | Guangdong |
China | Guangdong No.2 Provincial People's Hospital | Guangzhou | Guangdong |
China | Guangzhou Panyu Center Hospital | Guangzhou | Guangdong |
China | Liwan Hospital,Guangzhou Medical College | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Guangzhou Medical College | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Jinan University | Guangzhou | Guangdong |
China | The First Affiliated Hospital of Sun Yat-sen University | Guangzhou | Guangdong |
China | The Third Affiliated Hospital of Guangzhou Medical College | Guangzhou | Guangdong |
China | Guizhou People's Hospital | Guiyang | Guizhou |
China | The Affiliated Hospital of Guiyang Medical College | Guiyang | Guizhou |
China | Huizhou First Hospital | Huizhou | Guangdong |
China | Shanghai Xuhui District Central Hospital | Shanghai | Shanghai |
China | Zhongshan Hospital Fudan University | Shanghai | Shanghai |
China | Shaoguan Iron and Steel Group Company limited Hospital | Shaoguan | Guangdong |
China | The First People's Hospital of Shaoguan | Shaoguan | Guangdong |
China | Wengyuan County People's Hospital | Shaoguan | Guangdong |
China | Shenzhen Sixth People's Hospital | Shenzhen | Guangdong |
China | Tongji Hospital,Tongji Medical College of HUST | Wuhan | Hubei |
China | Affiliated Hospital of Guangdong Medical College | Zhanjiang | Guangdong |
China | The second people's Hospital,Zhanjiang | Zhanjiang | Guangdong |
China | Henan Provincial People's Hospital | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Guangzhou Medical University | Boehringer Ingelheim, Rundo International Pharmaceutical Research & Development Co.,Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference of trough FEV1 at 24 months from baseline | at 24 months | No | |
Secondary | difference of peak FEV1 at 24 months from baseline | at 24 months | No | |
Secondary | trough (pre-bronchodilator) FEV1 at 1, 6, 12 and 18 months | at 1, 6, 12 and 18 months | No | |
Secondary | quality of life (CAT and CCQ) | at 1, 3, 6, 9, 12, 15, 18 and 24 months | No | |
Secondary | symptom scores (mMRC dyspnoea scale) | at 1, 3, 6, 9, 12, 15, 18 and 24 months | No | |
Secondary | time to first COPD exacerbation | 24 months | No | |
Secondary | number of COPD exacerbation | 24 months | No | |
Secondary | severity of COPD exacerbation | 24 months | No | |
Secondary | Application of rescue medications | 24 months | No | |
Secondary | drop-out rate | 24 months | No | |
Secondary | adverse events | 24 months | Yes | |
Secondary | peak (post-bronchodilator) FEV1 at 1, 6, 12 and 18 months | at 1, 6, 12 and 18 months | No | |
Secondary | Yearly rate of decline in trough FEV1 from 1 month until completion of double-blind treatment | 24 months | No | |
Secondary | Yearly rate of decline in peak FEV1 from 1 month until completion of double-blind treatment | 24 months | No | |
Secondary | Yearly rate of decline in trough FVC from 1 month until completion of double-blind treatment | 24 months | No | |
Secondary | Yearly rate of decline in peak FVC from 1 month until completion of double-blind treatment | 24 months | No | |
Secondary | Yearly rate of decline in trough FEV1/FVC from 1 month until completion of double-blind treatment | 24 months | No | |
Secondary | Yearly rate of decline in peak FEV1/FVC from 1 month until completion of double-blind treatment | 24 months | No | |
Secondary | interval of COPD exacerbation | 24 months | No | |
Secondary | duration of COPD exacerbation | 24 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|